CAN10 

CAN10 is is a humanized monoclonal antibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CAN10 effectively impairs the proinflammatory and profibrotic effects of IL1RAP-related cytokines (IL-1, IL-33, and IL-36) in human umbilical cord endothelial cells and human dermal fibroblasts, which are critical to systemic sclerosis pathophysiology^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAN10 (mCAN10, mouse surrogate of CAN10) (10-20 mg/kg; i.p.; twice weekly; 7 weeks) reduces cutaneous and pulmonary fibrosis in a murine cGvHD model of systemic sclerosis, with significant improvements in dermal thickness, hydroxyproline content, myofibroblast counts, and lung Ashcroft scores^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3556  [NCBI]

Q9NPH3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.80 kDa

Liquid

Colorless to light yellow

N/A

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1X10⁶ HepG2 cells labeling IL1R3 with CAN10 (HY-P991267, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Grönberg C, et al. Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2024;83(9):1156-1168. Published 2024 Aug 27.  [Content Brief]